Valuation : Annexon, Inc.

Market Cap 747M 644M 609M 552M 1.04B 71.36B 1.04B 7.24B 2.78B 36.3B 2.81B 2.74B 115B P/E 2026 *
-3.8x
P/E 2027 * -4.03x
Enterprise Value 656M 566M 535M 485M 911M 62.71B 915M 6.36B 2.45B 31.9B 2.47B 2.41B 101B EV / Sales 2026 *
-
EV / Sales 2027 * 17.1x
Free-Float
94.44%
Yield 2026 *
-
Yield 2027 * -
1 day-4.83%
1 week-19.10%
Current month-20.24%
1 month-26.08%
3 months-16.35%
6 months-27.57%
Current year-21.51%
1 week 3.92
Extreme 3.92
4.78
1 month 3.92
Extreme 3.92
5.59
Current year 3.92
Extreme 3.92
7.18
1 year 2.32
Extreme 2.32
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 67 05/02/2021
Director/Board Member 56 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Director

175,000 0.0923%
28/5/26
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
11/5/26 Buy

Director

8,000 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-4.83%-19.10%+62.81%+74.34% 747M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.75%-4.56%+33.87%+230.16% 27.12B
Weighted average by Cap. -0.57%-2.87%+31.34%+170.39%

Financials

2026 *2027 *
Net sales - 38.92M 33.53M 31.75M 28.78M 53.99M 3.72B 54.26M 377M 145M 1.89B 146M 143M 5.98B
Net income -212M -182M -173M -156M -294M -20.22B -295M -2.05B -789M -10.29B -795M -777M -32.5B -209M -180M -171M -155M -290M -20B -292M -2.03B -780M -10.17B -786M -769M -32.15B
Net Debt -90.55M -78.02M -73.87M -66.96M -126M -8.65B -126M -877M -337M -4.4B -340M -333M -13.91B -80.71M -69.54M -65.84M -59.68M -112M -7.71B -113M -782M -301M -3.92B -303M -296M -12.4B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
92
Date Price Change Volume
11/09/26 USD 3.940 -4.83% 3,939,351
10/09/26 USD 4.140 -5.26% 4,204,451
09/09/26 USD 4.370 -6.42% 5,529,045
08/09/26 USD 4.670 -4.11% 2,139,858
04/09/26 USD 4.870 +0.62% 1,227,542
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.940USD
Average target price
15.29USD
Spread / Average Target
+287.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!